<div id="readability-page-1"><div><p>Health-care companies rose amid deal activity.</p><p>    Biomarin Pharmaceutical agreed to buy fellow biotechnology company Amicus Therapeutics for about $4.8 billion. Amicus founder and longtime leader, John Crowley started the company to find a cure for his two children's rare disease. </p><p>    Nine pharmaceutical companies, including Merck and British drug giant GSK, agreed to lower certain U.S. prices for their medicines in a new round of industry pacts with the Trump administration. </p><p>   Write to Rob Curran at rob.curran@dowjones.com </p><p>    (END) Dow Jones Newswires</p><p>12-19-25 1732ET</p></div></div>

葛兰素史克

爱美医疗

<p>医疗保健公司在交易活动中上涨。Biomarin Pharmaceutical 同意以约 48 亿美元收购生物技术公司 Amicus Therapeutics。Amicus 的创始人和长期领导者 John Crowley 创办该公司是为了寻找治愈他两个孩子罕见疾病的方法。包括默克和英国制药巨头 GSK 在内的九家制药公司同意在与特朗普政府的新一轮行业协议中降低其某些药品在美国的价格。请联系 Rob Curran，邮箱为 rob.curran@dowjones.com (完) 道琼斯新闻社 12-19-25 1732ET</p>

由于交易活动的增加，医疗保健行业上涨——医疗保健综述